Pharmaceutical Executive

??Our February issue is LIVE?? Pharmaceutical Executive has a brand ?? look??Read our 20th annual pipeline report??Engaging patient with a purpose?? Teva Pharmaceuticals CEO Richard Francis talks steering a company comeback??The shifting pharmacy landscape in 2025?? and so much more waiting for you, right here?? https://lnkd.in/ewKHmR84

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo.

?? In this part of her Pharmaceutical Executive video interview, Jennifer Butler, Chief Commercial Officer for Pleio, discusses why #pharma increasingly turning to #peertopatient platforms to educate patients, as well as relationships with trusted #patientcommunities and pharmacies.

?? In this Pharmaceutical Executive video interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how #tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient #telehealth.

?? Ron Lanton III, Esq., Partner, Lanton Law, discusses the legal and industry challenges posed by recent National Institute of Health budget cuts, #diversity bans in #clinicaltrials, and #pharmaceutical #supplychain disruptions due to #tariffs

"Patients with DPYD variations are 25.6X more likely to experience treatment related death on?standard‐dose fluoropyrimidine chemotherapy (5‐fluorouracil or capecitabine)." - Kristine Ashcraft, President and Founder of YouScript Read more about Kristine's thoughts on the recent FDA safety announcment regarding DPYD testing in "Screening for DPD: Q&A with Kristine Ashcraft" by Pharmaceutical Executive: https://lnkd.in/gSRnZ5gQ #DPD #DPYD #PGx #Pharmacogenomics #5FU #CancerTreatment

Immunic Therapeutics CEO Daniel Vitt sat down with Pharmaceutical Executive to discuss the high unmet needs in gastrointestinal and neuroinflammatory diseases and how the company is positioning itself to lead in these therapeutic areas. Hear about Immunic’s recent Phase Ib trial of IMU-856 and ongoing Phase III program of IMU-838 in multiple sclerosis: https://lnkd.in/gUtVyCed

Three of the new sites will focus primarily on producing ingredients for domestic usage.

?? In this Pharmaceutical Executive video interview, Jennifer Butler, Chief Commercial Officer for Pleio, the role #pharma should be playing in helping to ensure patients have access to health insights they can trust.